Shingrix®

BIOLOGICAL3 trials

Sponsors

Emory University, Duke University, Sinocelltech Ltd.

Conditions

Adverse Drug EventChicken PoxHerpes ZosterInjection Site ReactionPainQuality of LifeShinglesZoster

Phase 1

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine

Not yet recruitingNCT06801509

Sinocelltech Ltd.Herpes Zoster

Start: 2025-02-15End: 2027-10-10Target: 540Updated: 2025-01-30

Phase 2

Systems Biology of Zoster Vaccine

CompletedNCT04047979

Emory UniversityChicken Pox, Shingles, Zoster +1

Start: 2019-11-14End: 2023-10-30Updated: 2024-07-30

Phase 4

Simultaneous RZV and aIIV4 Vaccination

CompletedNCT05007041

Duke UniversityAdverse Drug Event, Injection Site Reaction, Pain +1

Start: 2021-09-21End: 2023-06-08Updated: 2024-07-11

Related Papers

Safety of Simultaneous Vaccination With Adjuvanted Zoster Vaccine and Adjuvanted Influenza Vaccine

JAMA Network Open2024-10-245 citations